Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Atomoxetine and DAW2022 on OSA Severity

ClinicalTrials.gov ID: NCT05350215

Public ClinicalTrials.gov record NCT05350215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 27, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Atomoxetine and DAW2022 on OSA Severity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.

Study identification

NCT ID
NCT05350215
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
18 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2022
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026
Last update posted
Jul 9, 2026

2022 – 2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Brigham and Women's Hospital Boston Massachusetts 02135 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Obstructive Sleep Apnea trials

Other public records listing Obstructive Sleep Apnea. Sorted by last update posted; newest first. Not a recommendation.

All Obstructive Sleep Apnea trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05350215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2026 · Synced Jul 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05350215 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →